<DOC>
	<DOCNO>NCT00107471</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , topotecan , work different way stop growth tumor cell , either kill cell stop divide . Colony-stimulating factor , G-CSF , may increase number immune cell find bone marrow peripheral blood may help immune system recover side effect chemotherapy . Radiation therapy use high-energy x-ray kill tumor cell . Topotecan may make tumor cell sensitive radiation therapy . Giving topotecan G-CSF together radiation therapy may effective treatment brain stem glioma . PURPOSE : This phase I/II trial study side effect best dose topotecan give together G-CSF radiation therapy see well work treat young patient newly diagnose brain stem glioma .</brief_summary>
	<brief_title>Topotecan , G-CSF , Radiation Therapy Treating Young Patients With Newly Diagnosed Brain Stem Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility escalate dose topotecan administer filgrastim ( G-CSF ) radiotherapy , term increase topotecan dose 25-50 % maximum tolerate dose ( MTD ) determine prior phase I study , young patient newly diagnose malignant intrinsic pontine brain stem glioma . ( Phase I ) - Determine dose-limiting toxic effect topotecan patient . ( Phase I ) - Determine 1-year event-free survival overall survival patient treat regimen ( MTD topotecan determine phase I ) . ( Phase II ) - Determine toxicity regimen patient . ( Phase II ) Secondary - Determine pharmacokinetics regimen patient . OUTLINE : This multicenter , phase I , dose-escalation study topotecan follow phase II study . - Phase I : Patients receive topotecan IV 30 minute follow radiotherapy daily , 5 day week 6-7 week . During chemoradiotherapy , patient also receive filgrastim ( G-CSF ) IV subcutaneously daily , need , blood count recover . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos topotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive topotecan ( MTD determine phase I ) , G-CSF , radiotherapy phase I . After completion study treatment , patient follow within 2 week , every 3 month 1.5 year , every 6 month 1.5 year , annually disease relapse . PROJECTED ACCRUAL : A total 3-72 patient ( 3-12 phase I 60 phase II ) accrue study within approximately 3 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis intrinsic pontine brain stem glioma within past 30 day Histologic confirmation require provided tumor pontine epicenter AND exhibit diffuse ( rather focal ) involvement ≥ 2/3 pons without extension adjacent medulla midbrain* NOTE : *Brain stem tumor meet criterion must histologically confirm grade III IV malignant glioma Measurable disease radiographic image Postoperative MRI require within past 30 day patient biopsy surgical resection No disseminate disease No neurofibromatosis type 1 PATIENT CHARACTERISTICS : Age 3 21 diagnosis Performance status Lansky 50100 % OR Karnofsky 50100 % Life expectancy At least 8 week Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 ( transfusion independent ) Hemoglobin ≥ 10.0 g/dL ( transfusion allow ) Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT &lt; 2.5 time ULN Renal Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR Creatinine base age follow : No great 0.8 mg/dL ( patient ≤ 5 year age ) No great 1.0 mg/dL ( patient 6 10 year age ) No great 1.2 mg/dL ( patient 11 15 year age ) No great 1.5 mg/dL ( patient 15 year age ) Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Not severely somnolent comatose Central cortical neurotoxicity scale &lt; grade 3 PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunomodulating agent Chemotherapy No concurrent anticancer chemotherapy Endocrine therapy Concurrent corticosteroid allow neurological deficit relate tumor Radiotherapy No prior radiotherapy Surgery See Disease Characteristics Prior biopsy surgical resection malignant brain stem glioma allow Other No prior therapy malignant brain stem glioma</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>untreated childhood brain stem glioma</keyword>
</DOC>